Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elevate-CKD phase 3 trial of elecoglipron in chronic kidney disease
MOH_2026-07-15_016936Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Elecoglipron once daily with Placebo once daily (2 arms). Primary endpoint: Composite renal outcome and all-cause mortality. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
elecoglipron
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on MOH_2026-07-15_016936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-07-15_016936.